Get the Stockscreener App
9.11
5.93%
0.51
After Hours:
9.10
-0.010
-0.11%
Monte Rosa Therapeutics Inc stock is traded at $9.11, with a volume of 627.58K.
It is up +5.93% in the last 24 hours and up +86.30% over the past month.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
See More
Previous Close:
$8.60
Open:
$8.73
24h Volume:
627.58K
Relative Volume:
0.29
Market Cap:
$546.79M
Revenue:
-
Net Income/Loss:
$-130.41M
P/E Ratio:
-3.5447
EPS:
-2.57
Net Cash Flow:
$-67.76M
1W Performance:
+8.97%
1M Performance:
+86.30%
6M Performance:
+118.99%
1Y Performance:
+203.67%
1-Day Range:
$8.61
$9.25
1-Week Range:
$8.0363
$9.25
52-Week Range:
$2.92
$12.40
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Name
Monte Rosa Therapeutics Inc
Sector
Industry
Phone
617-949-2643
Address
321 HARRISON AVENUE, BOSTON
Compare GLUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
9.11 | 546.79M | 0 | -130.41M | -67.76M | -2.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-13-22 | Initiated | UBS | Buy |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
View All
Monte Rosa Therapeutics Inc Stock (GLUE) Latest News
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference - The Manila Times
Monte Rosa Therapeutics CEO to Present at Piper Sandler Healthcare Conference | GLUE Stock News - StockTitan
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference - GlobeNewswire Inc.
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet - MSN
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Large Growth in Short Interest - MarketBeat
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference - GlobeNewswire
Monte Rosa Therapeutics to Present at Jefferies Healthcare Conference: MGD Innovation Spotlight | GLUE Stock News - StockTitan
FMR LLC Increases Stake in Monte Rosa Therapeutics Inc - GuruFocus.com
News Flash: Analysts Just Made A Sizeable Upgrade To Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Forecasts - Simply Wall St
Owning 47% shares,institutional owners seem interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), - Yahoo Finance
Wedbush Equities Analysts Raise Earnings Estimates for GLUE - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Earns “Outperform” Rating from Wedbush - Defense World
Monte Rosa Therapeutics Expands Pipeline with Novartis Deal - TipRanks
Monte Rosa Therapeutics earnings beat by $0.18, revenue topped estimates - Investing.com Canada
Monte Rosa Therapeutics: Q3 Earnings Snapshot - Barchart
Monte Rosa Therapeutics Inc (GLUE) Quarterly 10-Q Report - Quartzy
Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade - MSN
Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice - MSN
Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Monte Rosa Secures $2.1B Novartis Deal, Extends Cash Runway to 2028 in Major Pipeline Win | GLUE Stock News - StockTitan
Equities Analysts Issue Forecasts for GLUE FY2024 Earnings - Defense World
Biogen, Neomorph pact worth $1.45B for molecular glue degraders - BioWorld Online
Wedbush Research Analysts Lift Earnings Estimates for GLUE - MarketBeat
Monte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler - Yahoo Finance
Monte Rosa, Novartis Partner To Advance Molecular Glue Degraders - Contract Pharma
Monte Rosa Therapeutics Shares Skyrocket After $2.1 Billion Deal with Novartis - Yahoo Finance
This Biotech Stock Has Doubled Its Value Today—Here's Why - MSN
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - MSN
Monte Rosa Therapeutics Soars on Novartis Deal: A Molecular Glue Revolution - BP Journal
Monte Rosa Therapeutics stock hits 52-week high at $8.87 By Investing.com - Investing.com Canada
Novartis adds another degrader, this time from Monte Rosa - BioCentury
This Biotech Almost Doubled On A Massive Deal With Novartis - Investor's Business Daily
Monte Rosa Therapeutics (NASDAQ:GLUE) Reaches New 52-Week HighTime to Buy? - MarketBeat
Monte Rosa, Novartis have one in VAV1, sign $2.1B pact - BioWorld Online
Boston Biotech Announces Novartis Collaboration - Streetwise Reports
Monte Rosa Therapeutics Target of Unusually High Options Trading (NASDAQ:GLUE) - MarketBeat
Monte Rosa Therapeutics More Than Doubles on Novartis Agreement - MarketWatch
Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis - MSN
Monte Rosa: Novartis Deal Bolsters MGD Platform With Flush Of Cash (NASDAQ:GLUE) - Seeking Alpha
Novartis Signs Global License Agreement with Monte Rosa Therapeutics Worth up to $2.1 Billion to Advance MGD-based Therapeutics - BioPharm International
Monte Rosa Therapeutics, Evoke Pharma, and Autonomix Medical: The Top 3 Stocks Capturing Retail Attention - Barchart
Monte Rosa's stock doubles on multibillion dollar Novartis deal - The Business Journals
Top Gainer Monte Rosa Therapeutics’ Stock Enthralls Retail With Novartis Licensing Deal - Barchart
Monte Rosa Therapeutics stock hits 52-week high at $8.87 - Investing.com India
Monte Rosa scores $2.1B Novartis deal for molecular glue degraders - BioWorld Online
Monte Rosa soars as it inks global license deal with Novartis - The Pharma Letter
Monte Rosa joins with Novartis in ‘molecular glue’ drug deal - BioPharma Dive
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments” - The Globe and Mail
Monte Rosa Therapeutics, Inc Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders - Marketscreener.com
Monte Rosa Therapeutics Inc Stock (GLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):